Investing.com - Biomerieux reported on Wednesday second quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Biomerieux announced earnings per share of €1.93 on revenue of €820.9M. Analysts polled by Investing.com anticipated EPS of €2.22 on revenue of €719.4M.
Biomerieux shares are down 26% from the beginning of the year and are trading at €91.26 , down-from-52-week-high.They are under-performing the STOXX 600 which is down 14.9% from the start of the year.
Biomerieux follows other major Healthcare sector earnings this month
Biomerieux's report follows an earnings missed by Valneva on Thursday, August 11, 2022, who reported EPS of €-1.34 on revenue of €71.4M, compared to forecasts EPS of €-0.42 on revenue of €18.2M.
Cellectis had beat expectations on Thursday, August 4, 2022 with second quarter EPS of €-0.4132 on revenue of €2.72M, compared to forecast for EPS of €-0.4938 on revenue of €22.43M.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar